This peptide stack combines CJC-1295 DAC and Ipamorelin to synergistically increase natural growth hormone and IGF-1 levels. CJC-1295 DAC is a long-acting GHRH analog injected weekly, while Ipamorelin is a selective ghrelin-receptor agonist administered daily. The protocol involves a subcutaneous injection regimen designed to amplify endogenous growth hormone secretion through complementary mechanisms.
- Combines CJC-1295 DAC (2mg vial) and Ipamorelin (5mg vial).
- CJC-1295 DAC is a long-acting GHRH analog for weekly use.
- Ipamorelin is a selective ghrelin-receptor agonist for daily use.
- Synergistically amplifies endogenous growth hormone secretion.
- Ipamorelin is typically dosed before bed to align with natural GH release.
Reconstitution
Vial strength
—
Bacteriostatic water
—
Concentration
—
CJC-1295 DAC: 1 unit = 10 mcg; Ipamorelin: 1 unit ≈ 16.7 mcg
- 1For CJC-1295 DAC (2 mg vial): Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 2For CJC-1295 DAC: Inject slowly down the vial wall, avoiding foaming or direct stream onto the powder.
- 3For CJC-1295 DAC: Gently swirl or roll the vial until fully dissolved (do not shake).
- 4For CJC-1295 DAC: Label with the date and refrigerate at 2–8 °C (35.6–46.4 °F).
- 5For Ipamorelin (5 mg vial): Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 6For Ipamorelin: Inject slowly down the vial wall, avoiding foaming.
- 7For Ipamorelin: Gently swirl or roll the vial until dissolved (do not shake).
- 8For Ipamorelin: Label with the date and refrigerate at 2–8 °C (35.6–46.4 °F).
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-2 | CJC-1295 DAC: 1000 mcg once weekly; Ipamorelin: 100 mcg once daily | CJC-1295 DAC: 100 units; Ipamorelin: 6 units |
| Weeks 3-4 | CJC-1295 DAC: 1000 mcg once weekly; Ipamorelin: 150 mcg once daily | CJC-1295 DAC: 100 units; Ipamorelin: 9 units |
| Weeks 5-12 | CJC-1295 DAC: 1000 mcg once weekly; Ipamorelin: 200 mcg once daily | CJC-1295 DAC: 100 units; Ipamorelin: 12 units |
Protocol detail
| CJC-1295 DAC | 1 mg subcutaneously once per week on a consistent day. |
|---|---|
| Ipamorelin | Start at 100 mcg daily; titrate to 200 mcg by Week 5. |
| Timing | Ipamorelin before bed aligns with natural nocturnal GH release. |
| Cycle Length | 8–12 weeks standard; extend to 16 weeks if tolerated. |
| Injection Sites | Rotate abdomen, thighs, and upper arms. |
Overview at a glance
| Goal | Amplify endogenous GH/IGF-1 secretion through combined GHRH and ghrelin-receptor pathways. |
|---|---|
| Schedule | CJC-1295 DAC once weekly + Ipamorelin once daily for 8–16 weeks. |
| CJC-1295 DAC Dose | 1–2 mg weekly (standard: 1 mg). |
| Ipamorelin Dose | 100–300 mcg daily with gradual titration. |
| Storage | Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles. |
How it works
CJC-1295 DAC acts as a synthetic GHRH analog, stimulating pituitary GH release. Its Drug Affinity Complex (DAC) component binds to serum albumin, extending its half-life to about 6–8 days, resulting in sustained elevations of GH and IGF-1. Ipamorelin is a selective ghrelin-receptor agonist that triggers potent, rapid GH pulses without significantly impacting ACTH, cortisol, or prolactin. By working through distinct yet complementary pathways (GHRH receptor and ghrelin receptor), these peptides combine to synergistically enhance the body's natural growth hormone secretion.
Reported effects
- Improved body composition (lean mass & fat reduction)
- Sustained elevation of GH/IGF-1 levels
- Selective GH secretion without increased cortisol/ACTH
- Generally well-tolerated with transient injection site reactions
Reported side effects
- Transient injection-site reactions
- Water retention
- Mild headache
- Transient numbness/tingling
Storage
Lyophilised (unmixed)
Store at ≤-15 °C (5 °F), preferably ≤-50 °C (-58 °F) for long-term.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks. Avoid freeze-thaw cycles.
Supplies
| CJC-1295 DAC Vials (2mg each) | Approx. 4 vials for 8 weeks; 6 for 12 weeks; 8 for 16 weeks (at 1mg/week) |
|---|---|
| Ipamorelin Vials (5mg each) | Approx. 3 vials for 8 weeks; 4 for 12 weeks; 5 for 16 weeks (at 200mcg/day) |
| Insulin Syringes (U-100) | Approx. 8 per week; 64 for 8 weeks; 96 for 12 weeks; 128 for 16 weeks. Consider 30- or 50-unit syringes for Ipamorelin doses ≤10 units. |
| Bacteriostatic Water (10mL bottles) | Approx. 2 bottles for 8 weeks; 3 for 12 weeks; 4 for 16 weeks |
| Alcohol Swabs | Approx. 2 per day (×2 for Ipam + ×2 for CJC weekly); 2x 100-count boxes for 8 weeks; 3x 100-count boxes for 16 weeks. |
Important notes
- Use a new sterile insulin syringe for each injection.
- Dispose of used syringes in a sharps container.
- Rotate injection sites regularly to reduce irritation.
- Inject slowly and allow a few seconds before needle withdrawal.
- Document doses to ensure consistency.
- Keep CJC-1295 DAC and Ipamorelin in separate vials; do not pre-mix.
Frequently asked questions
How does combining CJC-1295 DAC and Ipamorelin differ from using them individually?
When combined, CJC-1295 DAC and Ipamorelin work synergistically to amplify growth hormone release. CJC-1295 DAC provides a sustained background stimulation of GH, while Ipamorelin triggers more potent pulsatile releases. This dual action often leads to more pronounced elevations in GH and IGF-1 compared to either peptide used alone.
Why is Ipamorelin recommended before bed?
Ipamorelin is typically administered before bed to coincide with the body's natural nocturnal growth hormone pulses. This timing helps to optimize the peptide's effectiveness by aligning with the natural physiological rhythm of GH secretion, potentially leading to better results and promoting restful sleep, which further supports GH release.
Can I pre-mix CJC-1295 DAC and Ipamorelin in the same vial or syringe?
No, it is strongly advised to keep CJC-1295 DAC and Ipamorelin in separate vials and to draw each peptide into its own syringe for injection. While some blends exist, combining different peptides might affect their stability, potency, and lead to inaccurate dosing due to varying concentrations and reconstitution requirements of individual compounds. Always follow specific reconstitution and dosing instructions for each peptide.
What should I do if I miss a dose of Ipamorelin?
If you miss a dose of Ipamorelin, simply take your next scheduled dose as usual. Do not double your dose, as this could lead to unintended side effects. Consistency is key, but occasional missed doses are not typically a cause for concern in longer-term protocols.
Educational reference only. These figures summarise how CJC-1295 DAC + Ipamorelin Stack is commonly described in research literature and supplier documentation, including the CJC-1295 DAC + Ipamorelin Stack listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
CJC-1295 DAC + Ipamorelin Stack (5 mg (+ 5 mg))
Synergistic GH release for enhanced anabolic signaling and body composition.
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
Ipamorelin (5 mg Vial)
Selective growth hormone secretagogue for lean mass, recovery, and fat metabolism.
GHRP-6 (10 mg Vial)
Mimics ghrelin to stimulate growth hormone release.